

#### Florida Medicaid Preauthorization and Notification List

Effective Date: Dec. 1, 2018 Revision Date: May 26, 2021

We have updated our preauthorization and notification list for Humana Medicaid plans in Florida. The list represents commonly reviewed services and medications and may require additional clinical information. Medications include those delivered in a physician office, clinic, outpatient or home setting.

#### Please note:

**Preauthorization** (i.e. prior authorization, precertification, preadmission) is a process through which a physician or other healthcare provider is required to obtain advance plan approval to cover an item or service.

**Notification** refers to the process through which a physician or other healthcare provider informs Humana of the intent to provide an item or service. Humana requests notification to help coordinate care for Humana-covered patients. Unlike preauthorization. Humana does not issue an approval or denial related to a notification.

Investigational and experimental procedures usually are not covered benefits. Please consult the member's Certificate of Coverage or contact Humana for confirmation of coverage.

#### **IMPORTANT NOTES:**

Florida Medicaid members:

- For Florida Medicaid plans, primary care physicians (PCPs) should ensure referrals are in place before services are provided.
- In addition to the information noted above, certain services outlined on the Medicaid Preauthorization and Notification List may not be applicable for practitioners affiliated with an independent practice association (IPA) via a capitated or delegated arrangement. Please refer to your provider agreement for clarification.
- Exclusions may change; refer to <a href="https://www.humana.com/provider/">https://www.humana.com/provider/</a> for the most upto-date information. Choose "Authorizations/Referrals" and then the appropriate topic.
- Humana Medicare Advantage (MA) and dual Medicare-Medicaid plans: This list does
  not affect Humana MA or dual Medicare-Medicaid plans. For a list of preauthorization
  requirements, please see our preauthorization page: <a href="https://doi.org/line.com/PAL"><u>Humana.com/PAL</u></a>

 Humana commercial members: This list does not affect Humana commercial plans. For a list of preauthorization requirements, please see our preauthorization page: Humana.com/PAL

Please note that urgent/emergent services do not require a referral or preauthorization.

Failure to obtain authorization/notification **prior to the date of service** could result in financial penalties for the practice and reduced member benefits, based on the healthcare provider's contract and the member's Certificate of Coverage. Services or medications provided without preauthorization may be subject to retrospective medical necessity review. We recommend that an individual practitioner making a specific request for services or medications verify benefits and preauthorization requirements with Humana prior to providing services.

#### How to request preauthorization:

Except where noted via links on the following pages, preauthorization requests for **medical** services may be initiated:

- Online via <u>Availity.com</u> (registration required)
- By calling Humana's interactive voice response (IVR) line at 800-523-0023

NOTE: Online preauthorization requests are encouraged. Additionally, clinical information for a medical service preauthorization request may be faxed to 813-321-7220.

Except where noted via links on the following pages, preauthorization requests for **medications** may be initiated:

- By sending a fax to 888-447-3430 (request forms are available at Humana.com/medpa)
- By calling 866-461-7273 (available Monday through Friday, 6 a.m. to 8 p.m. Eastern time)

This list is subject to change with notification; however, this list may be modified throughout the year for additions of new-to-market medications without notification via U.S. postal mail.

| Florida Medicaid Preauthorization and Notification List |  |  |
|---|--|--|
| Category  | Details  | Comments   |
| Inpatient admissions                                    | Acute hospital   | Transplant and planned inpatient medical and surgical admissions   |
|   | Acute rehab facilities   |  |
|   | Long-term acute care   |  |
|   | Skilled nursing facilities                                     |  |
|   | Mental health, substance use and partial                       | For north Florida (region 1 and 2), Access Behavioral Health will manage   |
|   | hospital/residential treatment                                 | For central and south Florida<br>(region 3,4,5,6,7,8,9,10 and<br>11) Beacon Behavioral<br>Health will manage           |
| Durable<br>medical                                      | Augmentative and alternative communicative systems             |  |
| equipment   | Cochlear and auditory brainstem implants                       |  |
| (DME)   | Other implantable/ semi-implantable hearing aids and devices   |  |
|   | Cranial orthotics  |  |
|   | DME repair   |  |
|   | Beds and accessories   | South Florida regions 9, 10<br>and 11 One Homecare<br>Solutions will manage<br>Humana will manage all<br>other regions |
|   | High frequency chest compression vests                         |  |
|   | Negative pressure wound therapy                                |  |
|   | Orthotics  |  |
|   | Personal Emergency Response System (PERS)                      |  |
|   | Prosthetics  |  |
|   | Continuous glucose monitoring devices and supplies             |  |
|   | Stimulator devices: bone growth, neuromuscular and spinal cord |  |
|   | Volume control ventilator                                      |  |

| Florida Medicaid Preauthorization and Notification List |  |   |
|---|--|---|
| Category  | Details  | Comments  |
|   | Wheelchairs and scooters   | South Florida regions 9, 10<br>and 11 One Homecare<br>Solutions will manage<br>Humana will manage all<br>other regions. |
|   | Nonivasive home ventilators  |   |
|   | Wearable cardiac devices (e.g., LifeVest®)                                       |   |
| Plastic surgery/<br>cosmetic                            | Blepharoplasty   |   |
|   | Breast procedures  | Excludes breast reconstruction following medically necessary mastectomy for breast                                      |
| Ancillary<br>Services                                   | Non-emergent medical transportation: cross-<br>country, air, water and ambulance |   |
| Outpatient services                                     | Electroencephalogram (EEG)   |   |
|   | Equine therapy   |   |
|   | Diagnostic Esophagogastroduodenoscopy (EGD)                                      |   |
|   | Facility-based Sleep Studies (PSG)   |   |
|   | Genetic/molecular diagnostic testing   |   |
|   | Infertility testing and treatment  |   |
|   | Physical, occupational and speech therapy  |   |
|   | Respiratory therapy  |   |
|   | Routine maternity care   | Notification only   |
|   | Single photon emission computerized tomography (SPECT) Scan                      |   |
| Other   | Home health/home infusion  | South Florida regions 9, 10 and 11 One Homecare Solutions will manage  Humana will manage all other regions.            |

| Florida Medicaid Preauthorization and Notification List |  |          |
|---|--|----------|
| Category  | Details  | Comments |
| Specialty drugs   | <ul> <li>Preauthorization required for the below list of specialty drugs when delivered in the physician's office, clinic, outpatient or home setting</li> <li>To request preauthorization or provide notification, please click here to access the fax forms</li> </ul> |          |

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                   | Generic                                   |
|-------------------------|---|
| Actemra IV              | tocilizumab                               |
| Adcetris                | brentuximab vedotin                       |
| Akynzeo IV              | fosnetupitant and palonosetron            |
| Aldurazyme              | laronidase                                |
| Aliqopa                 | copanlisib                                |
| Aloxi                   | palonosetron                              |
| Aralast NP <sup>1</sup> | alpha 1-proteinase inhibitor <sup>1</sup> |
| Aranesp                 | darbepoetin alfa                          |
| Asparlas*               | calaspargase pegol-mknl*                  |
| Bavencio                | avelumab                                  |
| Beleodaq                | belinostat                                |
| Belrapzo*               | bendamustine*                             |
| Bendeka                 | bendamustine hydrochloride                |
| Benlysta                | Belimumab                                 |
| Beovu*                  | brolucizumab-dbll*                        |
| Besponsa                | inotuzumab ozogamicin                     |
| Blincyto                | blinatumomab                              |
| Bortezomib <sup>1</sup> | bortezomib <sup>1</sup>                   |
| Botox                   | onabotulinumtoxinA                        |
| Brineura                | cerliponase alfa                          |
| Cerezyme                | imiglucerase                              |
| Cimzia                  | certolizumab pegol                        |
| Cinqair                 | reslizumab                                |

Find preauthorization request forms for the medications listed above <u>here.</u>

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                 | Generic                               |
|-----------------------|---------------------------------------|
| Cinvanti              | aprepitant                            |
| Cyramza               | ramucirumab                           |
| Dacogen               | decitabine                            |
| Darzalex              | daratumumab                           |
| Dupixent <sup>1</sup> | dupilumab <sup>1</sup>                |
| Durolane              | hyaluronic acid, stabilized           |
| Dysport               | abobotulinumtoxin A                   |
| Elaprase              | idursulfase                           |
| Empliciti             | elotuzumab                            |
| Entyvio               | vedolizumab                           |
| Epogen <sup>1</sup>   | epoetin alfa¹                         |
| Erwinaze              | asparaginase erwinia chrysanthemi     |
| Eskata <sup>1</sup>   | hydrogen peroxide <sup>1</sup>        |
| Euflexxa              | hyaluronate sodium                    |
| Evomela <sup>1</sup>  | melphalan <sup>1</sup>                |
| Exondys 51            | eteplirsen                            |
| Eylea*                | aflibercept*                          |
| Fasenra               | benralizumab                          |
| Flolan <sup>1</sup>   | epoprostenol (injection) <sup>1</sup> |
| Fulphila              | pegfilgrastim-jmdb                    |
| Fusilev <sup>1</sup>  | levoleucovorin calcium¹               |
| Gamifant*             | emapalumab-lzsg*                      |
| Gattex <sup>1</sup>   | teduglutide <sup>1</sup>              |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand  | Generic                             |
|--|-------------------------------------|
| Gazyva   | obinutuzumab                        |
| Gel-One  | sodium hyaluronate                  |
| Gelsyn-3   | sodium hyaluronate                  |
| Genvisc 850  | sodium hyaluronate                  |
| Granix   | tbo-filgrastim                      |
| H.P. Acthar Gel  | corticotropin                       |
| Herceptin  | trastuzumab                         |
| Herceptin Hylecta*   | trastuzumab and hyaluronidase-oysk* |
| Hyalgan <sup>1</sup>   | sodium hyaluronate <sup>1</sup>     |
| Hymovis  | sodium hyaluronate                  |
| Ilaris   | canakinumab                         |
| Imfinzi  | durvalumab                          |
| Imlygic  | talimogene laherparepvec            |
| Immune Globulin¹: Bivigam, Cutaquig, Cuvitru, Flebogamma DIF, Gamastan S/D, Gammagard S/D, Gammagard Liquid, Gammaked, Gammaplex, Gamunex-C, Hizentra, HyQvia, Octagam, Privigen | immune globulin <sup>1</sup>        |
| Inflectra  | infliximab-dyyb                     |
| Ixempra  | ixabepilone                         |
| Kadcyla  | ado-trastuzumab emtansine           |
| Keytruda   | pembrolizumab                       |
| Kineret <sup>1</sup>   | anakinra <sup>,1</sup>              |
| Krystexxa  | pegloticase                         |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                        | Generic                                   |
|------------------------------|---|
| Kymriah <sup>1,++</sup>      | tisagenlecleucel <sup>++</sup>            |
| Kyprolis                     | carfilzomib                               |
| Lartruvo                     | olaratumab                                |
| Lemtrada                     | alemtuzumab                               |
| Leukine                      | sargramostim                              |
| Levoleucovorin <sup>1</sup>  | levoleucovorin calcium¹                   |
| Libtayo*                     | cemiplimab-rwlc*                          |
| Lucentis*                    | ranibizumab*                              |
| Luxturna <sup>1</sup>        | voretigene neparvovec-rzyl <sup>1</sup>   |
| Macugen*                     | pegaptanib sodium*                        |
| Makena <sup>1</sup>          | hydroxyprogesterone caproate <sup>1</sup> |
| Marqibo                      | vincristine sulfate                       |
| Mepsevii                     | vestronidase alfa-vjbk                    |
| Monovisc                     | sodium hyaluronate                        |
| Mozobil                      | plerixafor                                |
| Mylotarg*                    | gemtuzumab ozogamicin*                    |
| Myobloc                      | rimabotulinumtoxinB                       |
| Neulasta <sup>1</sup>        | pegfilgrastim <sup>,1</sup>               |
| Neulasta Onpro <sup>,1</sup> | pegfilgrastim <sup>1</sup>                |
| Neupogen                     | filgrastim                                |
| Nivestym*                    | filgrastim-aafi*                          |
|                              | mepolizumab                               |
| Nucala                       | Перописитио                               |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                    | Generic                       |
|--------------------------|-------------------------------|
| Onivyde                  | irinotecan liposome injection |
| Opdivo                   | nivolumab                     |
| Orencia IV               | abatacept                     |
| Orthovisc                | sodium hyaluronate            |
| Palynziq <sup>1</sup>    | pegvaliase-pqpz <sup>1</sup>  |
| Parsabiv                 | etelcalcetide                 |
| Perjeta                  | pertuzumab                    |
| Portrazza                | necitumumab                   |
| Prevymis <sup>1</sup>    | letermovir <sup>1</sup>       |
| Procrit <sup>1</sup>     | epoetin alfa¹                 |
| Prolastin-C <sup>1</sup> | alpha 1-proteinase inhibitor¹ |
| Prolia <sup>1</sup>      | denosumab <sup>1</sup>        |
| Provenge                 | sipuleucel-T                  |
| Radicava                 | edaravone                     |
| Remicade                 | infliximab                    |
| Renflexis                | infliximab-abda               |
| Retacrit                 | epoetin alfa-epbx             |
| Retisert                 | fluocinolone acetonide        |
| Rituxan Hycela           | rituximab/hyaluronidase human |
| Sandostatin LAR          | octreotide                    |
| Simponi ARIA             | golimumab                     |
| Soliris                  | eculizumab                    |
| Spinraza                 | nusinersen                    |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                    | Generic                         |
|--------------------------|---------------------------------|
| Stelara                  | ustekinumab                     |
| Strensiq <sup>1</sup>    | asfotase alfa <sup>1</sup>      |
| Sublocade                | buprenorphine extended-release  |
| Supartz FX <sup>1</sup>  | sodium hyaluronate <sup>1</sup> |
| Sustol                   | granisetron                     |
| Synagis                  | palivizumab                     |
| Synribo                  | omacetaxine mepesuccinate       |
| Synvisc <sup>1</sup>     | hylan G-F 20 <sup>1</sup>       |
| Synvisc-One <sup>1</sup> | hyaluronan <sup>1</sup>         |
| Tecentriq                | atezolizumab                    |
| Triluron*                | hyaluronate sodium*             |
| Triptodur                | triptorelin                     |
| Trisenox                 | arsenic trioxide                |
| TriVisc                  | sodium hyaluronate              |
| Trogarzo                 | ibalizumab-uiyk                 |
| Tysabri                  | natalizumab                     |
| Tyvaso                   | treprostinil (inhaled)          |
| Udenyca*                 | pegfilgrastim-cbqv*             |
| Veletri <sup>1</sup>     | epoprostenol <sup>1</sup>       |
| Vidaza                   | azacitidine                     |
| Vimizim                  | elosulfase alfa                 |
| Visco-3 <sup>1</sup>     | sodium hyaluronate <sup>1</sup> |
| Visudyne                 | verteporfin                     |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.

Preauthorization is required for the following drugs when delivered in the physician's office, clinic, outpatient or home setting.

To request preauthorization or provide notification, please click here to access the fax forms.

| Brand                  | Generic                                    |
|------------------------|--|
| Vyxeos                 | daunorubicin/cytarabine                    |
| Xeomin                 | incobotulinumtoxinA                        |
| Xgeva <sup>1</sup>     | denosumab <sup>1</sup>                     |
| Xolair                 | omalizumab                                 |
| Yervoy                 | ipilimumab                                 |
| Yescarta <sup>++</sup> | axicabtagene ciloleucel <sup>++</sup>      |
| Zarxio                 | filgrastim-sndz                            |
| Zemaira <sup>1</sup>   | alpha 1-proteinase inhibitor <sup>1</sup>  |
| Zilretta               | triamcinolone acetonide                    |
| Ziextenzo*             | pegfilgrastim-bmez*                        |
| Zolgensma <sup>1</sup> | onasemnogene abeparvovec-xioi <sup>1</sup> |

Find preauthorization request forms for the medications listed above here.

<sup>\*</sup> New preauthorization requirement effective Mar. 1, 2021

<sup>▲</sup> New-to-market drug addition

<sup>&</sup>lt;sup>1</sup>All shared Healthcare Common Procedure Coding System (HCPCS) codes and Not Otherwise Classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

<sup>\*\*</sup> Preauthorization requests will be reviewed by **Humana National Transplant Network** and can be submitted by fax to 502-508-9300, telephone at 866-421-5663 or email to transplant@humana.com.